Genflow Biosciences is advancing SIRT6 gene therapy targeting age-related disease and metabolic dysfunction, with preclinical validation in aged dogs and planned human trials. SIRT6 activation represents a direct intervention in cellular aging pathways known to regulate energy metabolism, stress response, and tissue regeneration.
Key Points
- SIRT6-centenarian variant shows promise in preclinical aged dog models
- GF-1002 targets metabolic dysfunction and age-related disease simultaneously
- Gene therapy approach activates endogenous longevity mechanisms rather than external supplementation
Longevity Analysis
SIRT6 is a NAD-dependent histone deacetylase that coordinates cellular stress defense, energy production efficiency, and DNA repair capacity. By delivering a centenarian variant—a naturally occurring human gene variant associated with exceptional longevity—this approach addresses aging at the transcriptional level rather than symptomatically. The dual focus on metabolic dysfunction and age-related disease recognizes that these are downstream consequences of impaired cellular signaling and energy metabolism; restoring SIRT6 function targets the mechanism rather than the manifestation. The transition from aged dog models to human trials will clarify whether this genetic intervention translates to meaningful lifespan extension and functional improvement in metabolic and age-related conditions.
Original published by Longevity.Technology.